2-(Hydroxymethyl)-6-(propan-2-yloxy)oxane-3,4,5-triol | 5391-17-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(Hydroxymethyl)-6-(propan-2-yloxy)oxane-3,4,5-triol
• 英文别名: 2-(hydroxymethyl)-6-propan-2-yloxyoxane-3,4,5-triol
• CAS: 5391-17-3
• 化学式: C₉H₁₈O₆
• mdl: MFCD24393729
• 分子量: 222.24
• InChiKey: UOEFDXYUEPHESS-UHFFFAOYSA-N

物化性质

• 密度：
  1.34
• 物理描述：
  Solid
• 熔点：
  129-131°C

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 海关编码：
  2932999099

文献信息

• [EN] SSTR5 ANTAGONISTS<br/>[FR] ANTAGONISTES DE SSTR5
  申请人：KALLYOPE INC

  公开号：WO2021113368A1

  公开（公告）日：2021-06-10

  This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

  这项披露至少部分针对SSTR5拮抗剂，用于治疗涉及肠脑轴的疾病或疾病。在某些实施例中，SSTR5拮抗剂是肠限制性化合物。在某些实施例中，该疾病或疾病是代谢性疾病，如糖尿病、肥胖症、非酒精性脂肪肝炎（NASH）或营养紊乱，如短肠综合征。
• [EN] GPR119 AGONISTS<br/>[FR] AGONISTES DE GPR119
  申请人：KALLYOPE INC

  公开号：WO2021071837A1

  公开（公告）日：2021-04-15

  This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

  本公开涉及GPR119激动剂，至少部分用于治疗涉及肠脑轴的疾病或疾病。在某些实施例中，GPR119激动剂是肠限制化合物。在某些实施例中，该疾病或疾病是代谢性疾病，如糖尿病、肥胖症、非酒精性脂肪肝炎（NASH）或营养紊乱，如短肠综合征。
• Natural Products from Vinca
  申请人：San Ka-Yiu

  公开号：US20100048494A1

  公开（公告）日：2010-02-25

  New and useful compounds C. roseus cultured hairy roots are provided, by Isolating flavone glycosides together with a pharmaceutically acceptable carrier This is accomplished by immersing powdered the hairy roots in methanol to produce an extract, concentrating the extract, resuspending the extract in water, extracting the compound with organic solvent, and isolating the compound from the organic solvent.

  提供了一种从培养的C. roseus毛状根中分离出新的有用化合物的方法，该方法包括将粉末状毛状根浸泡在甲醇中以产生提取物，浓缩提取物，将提取物重新悬浮在水中，用有机溶剂提取化合物，并从有机溶剂中分离化合物，同时与药学上可接受的载体一起使用，分离黄酮苷。
• TARGETING LIPIDS
  申请人：Arbutus Biopharma Corporation

  公开号：EP3156077A1

  公开（公告）日：2017-04-19

  The present invention provides targeting lipids of structure (Cl) L100 - linker - L101, where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or -CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

  本发明提供了结构为（Cl）L100-连接体-L101的靶向脂质，其中L100为脂质、亲脂质、烷基、烯基或炔基，L101为配体或- (O )pO(CH2)q -配体，p为1-1000，q为1-20。此外，本发明还提供了向细胞输送治疗剂的组合物和方法。其中特别包括新型脂质和核酸-脂质颗粒，它们能有效地封装核酸，并在体内将封装的核酸有效地递送到细胞中。
• Desferrithiocin analogs and uses thereof
  申请人：University of Florida Research Foundation, Incorporated

  公开号：US10010535B2

  公开（公告）日：2018-07-03

  Iron overload is associated with pathological conditions such as oxidative stress, transfusional iron overload, thalassemia, primary hemochromatosis, secondary hemochromatosis, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, and reperfusion injury. The present invention provides methods and pharmaceutical compositions using desferrithiocin analogs of Formulae (A) and (J) for treating and/or preventing these pathological conditions, metal (e.g., iron, aluminum, a lanthanide, or an actinide (e.g., uranium)) overload conditions, and infectious diseases (e.g., malaria).

  铁超载与氧化应激、输血铁超载、地中海贫血、原发性血色素沉着病、继发性血色素沉着病、糖尿病、肝病、心脏病、癌症、辐射损伤、神经或神经退行性疾病、弗里德里希共济失调（FRDA）、黄斑变性、闭合性头部损伤、肠易激性疾病和再灌注损伤等病理状况有关。本发明提供了使用式（A）和式（J）的去铁硫霉素类似物治疗和/或预防这些病理状况、金属（如铁、铝、镧系元素或锕系元素（如铀））过载状况和传染病（如疟疾）的方法和药物组合物。